
BridgeBio Pharma
@BridgeBioPharma
Followers
2K
Following
107
Media
698
Statuses
743
Hope Through Rigorous Science Our mission is to discover, create, test and deliver transformative medicines to treat patients with genetic diseases. $BBIO
Palo Alto, California
Joined January 2021
Reminder to register 📆➡️ Join us for our investor webcast featuring Matthew Wicklund, M.D., FAAN of @UTHealthSA & LGMD2I/R9 exec team who will discuss LGMD2I/R9 and review BBP-418 progress.
0
0
7
We’re excited to join @TheEndoSociety at #ENDO2025 to share updates from our ADH1 program, including 42-month Phase 2b results from encaleret treatment, pediatric baseline characteristics from CLARIFY, our disease monitoring study, insights from our genetic testing program, &
0
0
7
Heading to PHARMACHON in SF on July 12? Join us alongside @thechandlerproj to learn about the latest in research developments.
0
1
5
Register 📆➡️ Don’t miss our LGMD2I/R9 investor webinar on Friday, July 11 at 8:00 AM ET with Matthew Wicklund, M.D., FAAN of @UTHealthSA.
0
1
5
💚👉 We’re inspired by the powerful patient and caregiver voices elevated by @CureLGMD2i. One example of this is Jennifer and Ryan’s story, which shows the true resilience of how families navigate a rare disease diagnosis like LGMD2I/R9.
0
3
6
Today, we announced the closure of a European royalty financing for our near-complete stabilizer in transthyretin amyloid cardiomyopathy of $300 million with HealthCare Royalty and @BlueOwlCapital. Learn more:
1
0
7
Learn more and register ➡️ Join us for an investor webinar on Friday, July 11 at 8:00 AM ET with Matthew Wicklund, M.D., FAAN of @UTHealthSA, where he will share an overview on limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).
0
0
5
❤️➡️ New publication in @JCVPOnline highlighting more data for acoramidis as a near-complete TTR stabilizer.
0
1
4
Our medical affairs team recently attended the Annual Meeting of the American Association of Heart Failure Nurses (@AAHFN), where we had the privilege of connecting with dedicated heart failure professionals and engaging in meaningful scientific discussions. We're grateful for
0
0
9
Over the past few weeks, the BridgeBio team joined four incredible advocacy conferences across Europe with @AISACOnlus, @BKMF, @assoappt, and @ANDO_Portugal. We’re so grateful for the opportunity to hear from the community and apply our learnings to our work.
0
0
2
Proud moment: BBOT, formerly a BridgeBio affiliate, is published in @Science Magazine !. BBO-10203 is designed to block the RAS-PI3Kα interaction stopping tumor growth without inducing hyperglycemia. A new chapter in precision oncology begins. Article:
0
1
16
Tune in here: 👉 We are proud that our CEO & Founder Neil Kumar, PhD, spoke at the @GoldmanSachs 46th Global Healthcare Conference 2025, where he shared updates on our #pipeline & our mission to put patients first by treating #geneticdiseases at their
0
0
7
We’re proud to share that our Chief Regulatory Officer, Adora Ndu, Pharm.D., J.D. participated in a panel at #NORD Disease Scientific Symposium on how to deliver impactful science for rare diseases by incorporating the patient voice into research design. The Symposium was a great
0
0
3
Our management team will present at the @GoldmanSachs 46th Annual Global Healthcare Conference 2025. We’ll discuss #pipeline progress, R&D strategy, and our approach to targeting #geneticdiseases at their source. 🔗 Investor webcast:
0
0
4
🎧 Hear how we’re building a new type of biotech company: In the past, many biotech companies overlooked rare diseases. In a One of One podcast with @TheTriumGroup, our CEO and founder, Neil Kumar shared how he built BridgeBio to fix this problem and
0
0
4
Caring for an infant or toddler with #achondroplasia may involve adaptations to support safety, comfort, and independence. Explore practical ideas for home and daycare on MyAchonJourney—along with more resources from the skeletal dysplasia community.
0
0
3